- Home
- CLLS vs QBTS Comparison
CLLS vs QBTS Comparison
Compare CLLS & QBTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- QBTS
- Stock Information
- Founded
- CLLS 1999
- QBTS 1999
- Country
- CLLS France
- QBTS Canada
- Employees
- CLLS N/A
- QBTS N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- QBTS Retail: Computer Software & Peripheral Equipment
- Sector
- CLLS Health Care
- QBTS Technology
- Exchange
- CLLS Nasdaq
- QBTS Nasdaq
- Market Cap
- CLLS 240.2M
- QBTS 194.5M
- IPO Year
- CLLS 2007
- QBTS N/A
- Fundamental
- Price
- CLLS $1.87
- QBTS $1.64
- Analyst Decision
- CLLS Buy
- QBTS Strong Buy
- Analyst Count
- CLLS 3
- QBTS 6
- Target Price
- CLLS $7.00
- QBTS $2.63
- AVG Volume (30 Days)
- CLLS 93.0K
- QBTS 11.9M
- Earning Date
- CLLS 11-04-2024
- QBTS 11-14-2024
- Dividend Yield
- CLLS N/A
- QBTS N/A
- EPS Growth
- CLLS N/A
- QBTS N/A
- EPS
- CLLS N/A
- QBTS N/A
- Revenue
- CLLS $36,042,000.00
- QBTS $9,424,000.00
- Revenue This Year
- CLLS $271.02
- QBTS $17.54
- Revenue Next Year
- CLLS $33.48
- QBTS $95.85
- P/E Ratio
- CLLS N/A
- QBTS N/A
- Revenue Growth
- CLLS 46.96
- QBTS 14.27
- 52 Week Low
- CLLS $1.70
- QBTS $0.68
- 52 Week High
- CLLS $3.77
- QBTS $2.44
- Technical
- Relative Strength Index (RSI)
- CLLS 47.58
- QBTS 63.60
- Support Level
- CLLS $1.70
- QBTS $0.98
- Resistance Level
- CLLS $2.00
- QBTS $2.15
- Average True Range (ATR)
- CLLS 0.11
- QBTS 0.21
- MACD
- CLLS 0.02
- QBTS 0.06
- Stochastic Oscillator
- CLLS 56.67
- QBTS 56.54
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About QBTS D-Wave Quantum Inc.
D-Wave Quantum Inc is engaged in the development and delivery of quantum computing systems, software, and services, and is the commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. The Company's mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modelling. D-Wave's annealing quantum computers are accessible through the Company's LeapTM cloud service.